Health

Argenx's VYVGART Hytrulo study in CIDP featured in the Lancet Neurology

Article Image

Argenx (NASDAQ:ARGX) announced today that its pivotal ADHERE study on VYVGART® Hytrulo has been published in The Lancet Neurology.

This study is the largest clinical trial to date investigating chronic inflammatory demyelinating polyneuropathy (CIDP), a severe autoimmune disorder.

"Since its approval in June, VYVGART Hytrulo is already transforming the lives of patients with CIDP," said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx.

The ADHERE study demonstrated substantial benefits of VYVGART Hytrulo, including a 61% reduction in the risk of relapse and rapid onset of action.

Additionally, 99% of trial participants opted for an open-label extension.

Meanwhile, VYVGART Hytrulo remains the first and only FDA-approved neonatal Fc receptor blocker for treating CIDP.

Following the announcement, Argenx's share price remained steady at $529.06. 

Disclaimer
Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.
Publisher
Grafa